Building a direct-sales base for specialty products in Asia
First written in FY2016. 1 of 3 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2018.
42 other companies' latest entry also says "Restated".
- FY2018RestatedAnnual report
「The company has already established local subsidiaries in South Korea and Taiwan and begun selling its own products there, and will also work to establish and strengthen its development structure with a view to direct sales in Europe and the US.」
The company has reaffirmed its policy of selling its own products through local subsidiaries in South Korea and Taiwan while preparing its organization with a view to direct sales in Europe and the US. - FY2017-Q2AdvancedAnnual report
「In May this year, following South Korea, the company began direct sales of Opdivo in Taiwan, its second overseas direct-sales market, for unresectable or metastatic melanoma and advanced or recurrent squamous non-small cell lung cancer.」
Following South Korea, the company also began direct sales of Opdivo in Taiwan, expanding its direct-sales base in Asia. - FY2016First statedAnnual report
「For specialty products such as anticancer drugs, the company has begun building a base for direct sales, starting in Asia, so that it can sell these products itself overseas. It has already established local subsidiaries in South Korea and Taiwan and put a direct-sales structure in place.」
The establishment of local subsidiaries and direct-sales structures in South Korea and Taiwan is described as a concrete means of building an overseas direct-sales business starting in Asia.